98%
921
2 minutes
20
Rapid detection of infectious diseases like COVID-19, flu, and dengue is crucial for healthcare professionals preparing for contagious outbreaks. Given the constant mutations in viruses and the recurring emergence of threats like Nipah and Zika, there is an urgent demand for a technology capable of distinguishing between infections that share similar symptoms. In this paper, we utilize laser-based Raman scattered signals from a drop of dried blood plasma, combined with generative artificial intelligence, to provide a rapid and precise diagnosis. Our optimized model exhibits exceptional performance, yielding high predictive scores of 96%, 98%, and 100% for flu, COVID-19, and dengue, respectively. The proposed Raman spectroscopic analysis, with a rapid turnaround time, can ensure a near-accurate diagnosis and proper quarantining of highly infectious cases. Furthermore, the potential extension of our method to include other viral diseases offers an alternative to the challenge of developing different diagnostic kits for each disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbio.70017 | DOI Listing |
J Infect Dis
September 2025
University of Veterinary Medicine Vienna, Infectiology, Vienna, Austria.
Frequent emergence of respiratory viruses with pandemic potential, like SARS-CoV-2 or influenza, underscores the need for broad-spectrum prophylaxis. Existing vaccines show reduced efficacy against newly emerged variants, and the ongoing risk of new outbreaks highlights the importance of alternative strategies to prevent infection and viral transmission. As respiratory viruses primarily enter through the nose, formulations targeting the nasal epithelium are attractive candidates to neutralize pathogens and thus prevent or minimize infection.
View Article and Find Full Text PDFPLOS Glob Public Health
September 2025
School of American and Global Studies, South Dakota State University, Brookings, South Dakota, United States of America.
It is possible that the negative attitudes toward COVID-19 vaccination developed by some people, such as self-identified Republicans, might spill over toward other vaccines. We conducted a survey experiment to investigate if mentioning COVID-19 vaccine in messages encouraging seasonal flu vaccination will negatively affect people's attitudes toward receiving a flu vaccine. The experiment was embedded in a survey fielded in South Dakota in April 2024.
View Article and Find Full Text PDFBMC Public Health
September 2025
Department of Mathematics, Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau, Gottlieb-Daimler-Str.48, Kaiserslautern, 67663, Germany.
We study the dynamics of coexisting influenza and SARS-CoV-2 by adapting a well-established age-specific COVID-19 model to a multi-pathogen framework. Sensitivity analysis and adjustment of the model to real-world data are used to investigate the influence of age-related factors on disease dynamics. Our findings underscore the critical role that transmission rates play in shaping the spread of influenza and COVID-19.
View Article and Find Full Text PDFOverview: We analysed Australian Immunisation Register (AIR) data, predominantly for National Immunisation Program funded vaccines, as at 2 April 2023 for children, adolescents and adults, focusing on the calendar year 2022 and on trends from previous years. This report aims to provide comprehensive analysis and interpretation of vaccination coverage data to inform immunisation policy and programs.
Children: Fully vaccinated coverage in Australian children in 2022 was 0.
J Infect Dev Ctries
August 2025
Department of Medical Microbiology, Faculty of Medicine, Ege University, Izmir 35100, Turkey.
Introduction: The aim of this study was to compare the performance of different clinical specimens-nasopharyngeal (NP) swabs collected by healthcare professionals (HCP-NP), self-collected nasal swabs (Sc-N), and saliva samples (S)-in diagnostic tests for investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and influenza A/B RNA.
Methodology: These clinical samples were collected from 404 symptomatic cases and tested with the SARS-CoV-2 and influenza A/B RNA tests on the cobas 6800 System of Roche Molecular Systems (Roche Molecular Systems, Pleasanton, USA). The SARS-CoV-2 or influenza virus infection status was determined for all patients based on the predefined criteria and corresponding algorithms.